BR112012000522A2 - método ex-vivo para testar se um paciente responderá terapeuticamente a um método de tratamento, uso da relação il10/ifnt como um biomarcador, kit para testar se um paciente responderá terapeuticamente a um método de tratamento, e, método ex-vivo para predizer se um paciente é ou não suscetível a sobreviver mais tempo após administração de uma composição imunogênica - Google Patents

método ex-vivo para testar se um paciente responderá terapeuticamente a um método de tratamento, uso da relação il10/ifnt como um biomarcador, kit para testar se um paciente responderá terapeuticamente a um método de tratamento, e, método ex-vivo para predizer se um paciente é ou não suscetível a sobreviver mais tempo após administração de uma composição imunogênica

Info

Publication number
BR112012000522A2
BR112012000522A2 BR112012000522A BR112012000522A BR112012000522A2 BR 112012000522 A2 BR112012000522 A2 BR 112012000522A2 BR 112012000522 A BR112012000522 A BR 112012000522A BR 112012000522 A BR112012000522 A BR 112012000522A BR 112012000522 A2 BR112012000522 A2 BR 112012000522A2
Authority
BR
Brazil
Prior art keywords
patient
therapeutically
respond
treatment method
testing whether
Prior art date
Application number
BR112012000522A
Other languages
English (en)
Inventor
Benoît Grellier
Bruce Acres
Original Assignee
Transgène S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgène S A filed Critical Transgène S A
Publication of BR112012000522A2 publication Critical patent/BR112012000522A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1738—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112012000522A 2009-07-10 2010-07-06 método ex-vivo para testar se um paciente responderá terapeuticamente a um método de tratamento, uso da relação il10/ifnt como um biomarcador, kit para testar se um paciente responderá terapeuticamente a um método de tratamento, e, método ex-vivo para predizer se um paciente é ou não suscetível a sobreviver mais tempo após administração de uma composição imunogênica BR112012000522A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305672 2009-07-10
PCT/EP2010/059635 WO2011003905A1 (en) 2009-07-10 2010-07-06 Biomarker for selecting patients and related methods

Publications (1)

Publication Number Publication Date
BR112012000522A2 true BR112012000522A2 (pt) 2016-02-16

Family

ID=42634974

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012000522A BR112012000522A2 (pt) 2009-07-10 2010-07-06 método ex-vivo para testar se um paciente responderá terapeuticamente a um método de tratamento, uso da relação il10/ifnt como um biomarcador, kit para testar se um paciente responderá terapeuticamente a um método de tratamento, e, método ex-vivo para predizer se um paciente é ou não suscetível a sobreviver mais tempo após administração de uma composição imunogênica

Country Status (20)

Country Link
US (1) US9261512B2 (pt)
EP (1) EP2452194B1 (pt)
JP (1) JP5650212B2 (pt)
KR (1) KR20120089619A (pt)
CN (1) CN102483405B (pt)
AU (1) AU2010270313B2 (pt)
BR (1) BR112012000522A2 (pt)
CA (1) CA2767458A1 (pt)
DK (1) DK2452194T3 (pt)
ES (1) ES2558729T3 (pt)
HU (1) HUE028240T2 (pt)
IL (1) IL216083A (pt)
MX (1) MX337287B (pt)
NZ (1) NZ596325A (pt)
PH (1) PH12011502635A1 (pt)
RU (1) RU2552292C2 (pt)
SG (1) SG176619A1 (pt)
TW (1) TWI529392B (pt)
WO (1) WO2011003905A1 (pt)
ZA (1) ZA201200110B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6389122B2 (ja) 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗ｓｍａｄ７治療に対する応答性をモニターするための方法
AU2013231230A1 (en) * 2012-03-13 2014-08-07 AbbVie Deutschland GmbH & Co. KG Method for selecting or identifying a subject for V1B antagonist therapy
US20140244556A1 (en) * 2013-02-27 2014-08-28 Abdul Saleh Methods for and apparatus generating automated pharmaco genetics correlation
AU2014284124B2 (en) 2013-06-20 2020-03-12 Immunexpress Pty Ltd Biomarker identification
JP2017512304A (ja) 2014-02-06 2017-05-18 イミューンエクスプレス・プロプライエタリー・リミテッドＩｍｍｕｎｅＸｐｒｅｓｓ Ｐｔｙ Ｌｔｄ バイオマーカーシグネチャー法ならびにそのための装置およびキット
FR3072973B1 (fr) * 2017-10-26 2022-02-11 Univ Pierre Et Marie Curie Paris 6 Particules pseudo-virales utiles pour traiter des dysfonctionnements immunitaires
RU2705398C1 (ru) * 2018-08-17 2019-11-07 федеральное государственное бюджетное образовательное учреждение высшего образования "Новосибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО НГМУ Минздрава России) Способ прогнозирования эффективности применения средства для повышения относительного содержания высокодифференцированных клеток в аденокарциноме молочной железы и композиция для его осуществления

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US6054438A (en) 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
WO1995031105A1 (en) 1994-05-13 1995-11-23 Thomas Jefferson University A method of inducing an immune response using vaccinia virus recombinants
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
AU731860B2 (en) 1996-07-25 2001-04-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
CA2282300C (en) 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
WO1998039017A1 (en) 1997-03-07 1998-09-11 Akira Hayashi Immunotherapeutic agent for cancer containing nucleoidal component of bacterium as active ingredient
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
EP1147181B1 (en) 1999-02-04 2004-05-12 Geron Corporation Replicative virus driven by the promoter for telomerase reverse transcriptase for use in treating cancer
JP4802366B2 (ja) 1999-02-22 2011-10-26 トランスジェン・ソシエテ・アノニム 精製ウイルス調製物の取得方法
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
WO2000073479A1 (en) 1999-05-28 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6110135A (en) 1999-06-17 2000-08-29 Becton, Dickinson And Company Elbow brace with movable support
CN1382218A (zh) 1999-11-15 2002-11-27 昂尼克斯药物公司 溶瘤腺病毒
AUPQ520800A0 (en) 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
UA76731C2 (uk) 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
JP2004533421A (ja) 2001-03-27 2004-11-04 バイオミラ，インコーポレイテッド Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
EP1417353A4 (en) * 2001-07-20 2005-08-03 Univ Texas METHODS AND COMPOSITIONS ASSOCIATED WITH HPV ASSOCIATED PENCILS AND CANNULAR WELLS, INCLUDING CIN
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
US6928476B2 (en) 2002-08-23 2005-08-09 Mirra, Inc. Peer to peer remote data storage and collaboration
FR2855758B1 (fr) 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
US20050014734A1 (en) * 2003-07-18 2005-01-20 Genovate Biotechnology Co., Ltd. Modulation of interleukin-10 by DHEA
EP1694990A4 (en) 2003-11-24 2009-12-09 Microstaq Inc MICRO-VALVE DEVICE FOR CONTROLLING A VARIABLE DISPLACEMENT COMPRESSOR
US8871250B2 (en) 2005-06-28 2014-10-28 Oncothyreon Inc. Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
HRP20150360T1 (hr) 2007-11-19 2015-05-08 Transgene Sa Poksvirusni onkolitiäśki vektori
RU2503717C2 (ru) 2007-11-19 2014-01-10 Трансжене Са Поксвирусные онколитические векторы
ES2555858T3 (es) 2009-03-24 2016-01-11 Transgene Sa Biomarcador para el control de pacientes

Also Published As

Publication number Publication date
NZ596325A (en) 2013-11-29
JP2012533052A (ja) 2012-12-20
EP2452194B1 (en) 2015-11-11
WO2011003905A1 (en) 2011-01-13
HUE028240T2 (en) 2016-12-28
CN102483405B (zh) 2015-12-02
AU2010270313B2 (en) 2014-05-22
ES2558729T3 (es) 2016-02-08
MX2012000509A (es) 2012-02-13
US20120115249A1 (en) 2012-05-10
HK1165206A1 (en) 2012-09-28
AU2010270313A1 (en) 2011-11-24
CN102483405A (zh) 2012-05-30
ZA201200110B (en) 2012-10-31
RU2552292C2 (ru) 2015-06-10
PH12011502635A1 (en) 2012-11-12
JP5650212B2 (ja) 2015-01-07
DK2452194T3 (en) 2015-11-30
KR20120089619A (ko) 2012-08-13
IL216083A (en) 2015-04-30
EP2452194A1 (en) 2012-05-16
RU2012103932A (ru) 2013-08-20
US9261512B2 (en) 2016-02-16
IL216083A0 (en) 2012-01-31
MX337287B (es) 2016-02-22
TW201105970A (en) 2011-02-16
TWI529392B (zh) 2016-04-11
SG176619A1 (en) 2012-01-30
CA2767458A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
BR112012000522A2 (pt) método ex-vivo para testar se um paciente responderá terapeuticamente a um método de tratamento, uso da relação il10/ifnt como um biomarcador, kit para testar se um paciente responderá terapeuticamente a um método de tratamento, e, método ex-vivo para predizer se um paciente é ou não suscetível a sobreviver mais tempo após administração de uma composição imunogênica
UY32970A (es) Acidos 3-fenilpropionicos sustituidos y su uso
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
SV2011004019A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
BRPI0906261A2 (pt) "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
UY31228A1 (es) Ariloxazoles sustituidos y su uso
BR112013013167A8 (pt) inibidores de bromodomínio e usos dos mesmos
CL2008003549A1 (es) Compuestos derivados de glucocorticoides; procedimientos de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades a la piel como eczema, afecciones a la nariz, garganta y pulmones como rinitis o asma, enfermedades inflamatorias del intestino, oculares y autoinmunes.
BRPI0923589A2 (pt) uso de uma composição espumável essencialmente livre de ingredientes farmaceuticamente ativos para o tratamento da pele humana.
BRPI0813000A2 (pt) Composições terapêuticas e uso das mesmas
BR112012029746A2 (pt) composição para tratamento da pele, método para fornecer um efeito microbicida para pele e uso de uma combinação
BR112012031416A2 (pt) solução aceleradora e uso de uma solução aceleradora
PA8794401A1 (es) Acidos 6-fenilnicotinicos sustituidos y su uso
BRPI0920222A2 (pt) composições catalisadoras e métodos de produção e uso das mesmas
BRPI1011912A2 (pt) l-serina para uso como medicamento para prevenir e/ou tratar uma reação inflamatória da pele.
BRPI1012250A2 (pt) composição lubrificante, e, uso de uma composição lubrificante
BRPI1009741A2 (pt) composição, método para prevenir ou tratar a mucosite em paciente mamífero, composição farmacêutica para adminstração tópica, e uso de uma composição
BR112013015798A2 (pt) composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, e, composição farmacêutica
MX2012002909A (es) Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
BR112012011770A2 (pt) inalador para uma formulação de inalação e uso de um inalador para formulação de inalação
UY30582A1 (es) Derivados de acido 2-fenoxinicotinico y su uso

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]